$TEM 0.21 Weak

Notable posts

• @StockSavvyShay neutral 664 eng

  NEXT WEEKS EARNINGS ARE MASSIVE • Monday | $APLD, $NVTS, $CDNS, $AMKR • Tuesday | $BE, $KLAC, $PYPL, $V, $TER, $ENPH • Wednesday | $MSFT, $META, $HOOD, $ARM, $QCOM, $SOFI, $VRT, $LMND, $LRCX, $VKTX, $FTNT, $CVNA • Thursday | $AAPL, $AMZN, $COIN, $RBLX, $RDDT, $TEM, $RIVN, $FSLR, $MA, $PGY, $MSTR, $AXTI, $NXT • FRIDAY | $CVX, $XOM, $ABBV, $CCJ, $MRNA

  view on X →
• @StockSavvyShay neutral 241 eng

  $TEM is acquiring $PSNL for $1.5B adding its NeXT Personal MRD technology to expand deeper into cancer recurrence monitoring. Personalis shareholders will receive $16.25 per share with the deal structured as all stock but allowing Tempus to pay up to 50% in cash. https://t.co/1cGhr0PhJX

  view on X →
• @StockSavvyShay neutral 163 eng

  $TEM Q2 EARNINGS • Revenue $383M vs Est. $380M • EPS ($0.04) vs Est. ($0.15) • EBITDA $8M vs Est. $9M • Diagnostics Revenue: $289M (+20% YoY) FY26 Guidance • Revenue $1.61B vs Est. $1.59B • EBITDA $65M vs Est. $65M Tempus says its Personalis partnership has already proven the value of combining “highly sensitive MRD technology” with its commercial infrastructure.

  view on X →
• @enrichtrades bullish 159 eng

  Watchlist for tomorrow, 7/8: Momentum is still there. Stay patient. Don't overtrade. One A+ setup is all you need. 7 straight winning trades. Recent: $IBM +370% $LLY +200% Watching: $DELL $IBM $PLTR $UBER $META Healthcare: $LLY $TEM $VKTX $UNH $OSCR Let price action confirm. React, don't predict. Preserve your capital and let the leaders do the heavy lifting.

  view on X →
• @wallstengine neutral 157 eng

  Tempus AI $TEM to ACQUIRE Personalis $PSNL for $1.5 billion, expanding deeper into cancer recurrence monitoring Personalis shareholders will receive $16.25 per share, a 6% premium to the latest close and a 28% premium to the unaffected 30-day average. The deal brings Personalis’ NeXT Personal MRD technology into Tempus’ AI and clinical data platform, strengthening its position across cancer diagnosis, treatment selection, and recurrence monitoring. The transaction is structured as an all-stock deal, though Tempus can pay up to 50% in cash.

  view on X →
• @wallstengine neutral 127 eng

  Tempus $TEM highlighted real-world NHS results for Paige Prostate AI, published in Nature Digital Medicine. Across 1,000+ prostate biopsy patients, AI-assisted review led to an updated diagnosis or Grade Group in 5% of cases, with 1.3% potentially changing clinical management. Also, WOLF is running another free-to-enter 2-week stock picking competition on Gamestock, with $400 in prizes for the top 3. You can join here: https://t.co/gbV9n5yZlO

  view on X →
• @ProfKayaFinance bullish 86 eng

  😎😎 $META %10 $PLTR %9 $AXON %7 $TEM %6 https://t.co/lEli2BkEv3

  view on X →
• @wallstengine bullish 82 eng

  TEMPUS $TEM Q2’26 EARNINGS HIGHLIGHTS 🔹 Revenue: $382.5M (Est. $380M) 🟢; +22% YoY 🔹 Adj. EPS: -$0.04 (Est. -$0.14) 🟢 🔹 Adjusted EBITDA: $8.0M (Est. $8.5M) 🟡 🔹 Net Income: $5.6M (Est. -$25.2M) 🟢; includes $98.5M in unrealized gains on marketable securities Raises FY26 Guide: 🔹 Revenue: $1.60B-$1.61B (Est. $1.59B) 🟡 🔹 Adjusted EBITDA: ~$65M (Est. $63.1M) 🟢 Segment Net Revenue: 🔹 Diagnostics: $289.3M; +20% YoY 🔹 Data and Applications: $93.2M; +28% YoY Other Q2 Metrics: 🔹 Gross Profit: $246.5M; +26% YoY 🔹 Oncology Volume Growth: 31% YoY 🔹 Data Licensing (Insights) Revenue Growth: +36% YoY Comments: 🔸 “Our strategy is working given the investments we have made in AI over the past several years are driving some of the best growth rates we have seen in our two largest businesses - Oncology Diagnostics and Data Licensing.” 🔸 “Through our existing collaboration with Personalis, we have already demonstrated the strength of combining highly sensitive MRD technology with our commercial infrastructure.”

  view on X →